dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
Company profile
Ticker
DVAX
Exchange
Website
CEO
Ryan Spencer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Dynavax GmbH ...
IRS number
330728374
DVAX stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
12 Mar 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 24
8-K
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
8 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
2 Nov 23
8-K
Entry into a Material Definitive Agreement
13 Sep 23
8-K
Departure of Directors or Certain Officers
1 Sep 23
S-3ASR
Automatic shelf registration
3 Aug 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
Transcripts
DVAX
Earnings call transcript
2023 Q4
22 Feb 24
DVAX
Earnings call transcript
2023 Q3
2 Nov 23
DVAX
Earnings call transcript
2023 Q2
3 Aug 23
DVAX
Earnings call transcript
2023 Q1
2 May 23
DVAX
Earnings call transcript
2022 Q4
23 Feb 23
DVAX
Earnings call transcript
2022 Q3
4 Nov 22
DVAX
Earnings call transcript
2022 Q2
5 Aug 22
DVAX
Earnings call transcript
2022 Q1
6 May 22
DVAX
Earnings call transcript
2021 Q4
28 Feb 22
DVAX
Earnings call transcript
2021 Q3
5 Nov 21
Latest ownership filings
4
Justin Burgess
19 Mar 24
4
Justin Burgess
4 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
4
David F Novack
20 Feb 24
4
Ryan Spencer
20 Feb 24
4
Kelly MacDonald
20 Feb 24
4
Robert Janssen
20 Feb 24
4
Justin Burgess
20 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
4
David F Novack
13 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 154.78 mm | 154.78 mm | 154.78 mm | 154.78 mm | 154.78 mm | 154.78 mm |
Cash burn (monthly) | 24.09 mm | 3.67 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 143.65 mm | 21.86 mm | n/a | n/a | n/a | n/a |
Cash remaining | 11.13 mm | 132.91 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | 0.5 | 36.3 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 226 |
Opened positions | 35 |
Closed positions | 23 |
Increased positions | 84 |
Reduced positions | 64 |
13F shares | Current |
---|---|
Total value | 1.84 tn |
Total shares | 131.01 mm |
Total puts | 80.80 k |
Total calls | 606.60 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 21.24 mm | $313.75 bn |
FHI Federated Hermes Inc - Ordinary Shares | 12.63 mm | $186.53 bn |
Vanguard | 9.15 mm | $135.10 bn |
STT State Street | 8.26 mm | $121.94 bn |
Deep Track Capital | 6.76 mm | $99.80 bn |
Chicago Capital | 5.79 mm | $85.54 bn |
Bain Capital Life Sciences Fund | 4.91 mm | $76.74 mm |
Dimensional Fund Advisors | 3.74 mm | $55.22 bn |
GS Goldman Sachs | 2.95 mm | $43.61 bn |
Geode Capital Management | 2.70 mm | $39.90 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Mar 24 | Justin Burgess | Stock Options Common Stock | Grant | Acquire A | No | No | 11.7 | 20,000 | 234.00 k | 20,000 |
1 Mar 24 | Justin Burgess | Common Stock | Sell | Dispose S | No | No | 12.78 | 13,425 | 171.57 k | 0 |
1 Mar 24 | Justin Burgess | Common Stock | Sell | Dispose S | No | No | 12.78 | 7,101 | 90.75 k | 13,425 |
1 Mar 24 | Justin Burgess | Common Stock | Option exercise | Acquire M | No | No | 9.41 | 2,767 | 26.04 k | 20,526 |
1 Mar 24 | Justin Burgess | Common Stock | Option exercise | Acquire M | No | No | 11.12 | 4,334 | 48.19 k | 17,759 |
1 Mar 24 | Justin Burgess | StockOptions Common Stock | Option exercise | Dispose M | No | No | 9.41 | 2,767 | 26.04 k | 0 |
1 Mar 24 | Justin Burgess | Stock Options Common Stock | Option exercise | Dispose M | No | No | 11.12 | 4,334 | 48.19 k | 8,666 |
12 Feb 24 | Janssen Robert | Common Stock | Payment of exercise | Dispose F | No | No | 12.82 | 1,531 | 19.63 k | 58,684 |
12 Feb 24 | David F Novack | Common Stock | Payment of exercise | Dispose F | No | No | 12.82 | 3,151 | 40.40 k | 20,883 |
12 Feb 24 | Ryan Spencer | Common Stock | Payment of exercise | Dispose F | No | No | 12.82 | 11,684 | 149.79 k | 200,628 |
News
Dynavax Technologies: Q4 Earnings Insights
22 Feb 24
Dynavax Technologies Q4 Sales $55.60M Beat $52.73M Estimate
22 Feb 24
Earnings Scheduled For February 22, 2024
22 Feb 24
Goldman Sachs Initiates Coverage On Dynavax Technologies with Neutral Rating, Announces Price Target of $20
1 Feb 24
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
8 Jan 24
Press releases
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
27 Feb 24
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance
22 Feb 24
Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024
8 Feb 24
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
8 Jan 24
Dynavax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
3 Jan 24